The Zhitong Finance App learned that Giant Biotech (02367) rose by more than 4%. As of press release, it had risen 4.35% to HK$41.95, with a turnover of HK$806.683 million.
Guotai Junan released a research report saying that Juzi Biotech's Kefu Mei and Kelijin 38 promoted high growth. The star product, Collagen Stick, maintained a strong trend, and the Klein Big Mask King Mask was impressive, and they are optimistic that performance will continue to rise high under the dividends of the recombinant collagen racetrack. Juzi Biocard has grown rapidly and restructured the collagen circuit. The cosmetics business continues to expand its product line, and subsequent medical and aesthetic products are expected to be relayed.
CMB International stated that while maintaining Giazi Biotech's “buy” rating, the target price is HK$48.84. Our online sales in the US continued to grow, and injectable collagen products were approved during the year. The bank previously stated that Giant Biotech continues the new trend of promoting skincare products, and the company's four injectable collagen products are progressing steadily. Two of these are expected to be approved in 2024, contributing to increased performance.